The dental and medicinal benefits board, TLV, has decided on 19 October that ORGOVYX® (relugolix), tablets for the treatment of advanced hormone-sensitive prostate cancer in Sweden, should be included in the pharmaceutical benefit scheme from…

"At Accord, we work to develop new treatment options that meet the needs of patients and healthcare, where Orgovyx is a good example that benefits both parties, with reduced side effects and a more comfortable administration for patients and it releases resources for the healthcare system when no injections are needed ." says Jan Stenfors, medical & scientific advisor for the Nordics and Baltics. " At Accord, we work to develop new treatment options that meet the needs of patients and...

"At Accord, we work to develop new treatment options that meet the needs of patients and healthcare, where Orgovyx is a good example that benefits both parties, with reduced side effects and a more comfortable administration for patients and it releases resources for the healthcare system when no injections are needed ." says Jan Stenfors, medical & scientific advisor for the Nordics and Baltics.

Anders Bjartell, professor and chief physician in urology at Skåne University Hospital in Malmö, comments on the subsidy approval in this way: "It is gratifying to be able to offer our patients with advanced prostate cancer a castration treatment in tablet form with a very fast-acting effect. After treating patients in the HERO study, we are now looking forward to evaluate this new exciting medicine on a larger scale."

Prostate cancer is the most common form of cancer in men Sweden and is also the most common cause of cancer-related death among men. There are approximately 10,000 new cases per year, with the median age at diagnosis being 70.5 years. Most patients who cannot be cured by surgery or radiation receive castration treatment, often with the addition of other medical treatment.⁴

About Accord Healthcare

Accord Healthcare is one of the fastest growing pharmaceutical companies in Europe. Our global organization enables us to deliver essential and affordable healthcare medicines that benefit patients worldwide.

Accords is always looking for ways to improve products and increase patient access to them.

We provide over 40 oncology drugs, and have a large number of additional substances are in our pipeline, with several new market approvals expected in the next five years. We particularly focus on the major tumor diseases such as breast and prostate cancer, in addition to hematological and cancer supportive care.

In May 2022, Accord was selected by Myovant Sciences as its commercial partner for the European commercialization of relugolix for the treatment of advanced hormone-sensitive prostate cancer.

Referenser:

Logo - https://mma.prnewswire.com/media/2255033/4357264/Accord_Healthcare_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/the-dental-and-medicinal-benefits-board-tlv-has-decided-on-19-october-that-orgovyx-relugolix-tablets-for-the-treatment-of-advanced-hormone-sensitive-prostate-cancer-in-sweden-should-be-included-in-the-pharmaceutical-benefit-301964940.html